title: Effects of a selective A1-adenosine receptor agonist on heart rate and heart rate variability during permanent atrial fibrillation.
abstract: BACKGROUND
  Mean heart rate and irregularity of the rate, i.e., heart rate variability (HRV), are two aspects of heart rate during atrial fibrillation (AF). An important goal of AF therapy is to control mean heart rate during exercise; the determinants of HRV during AF remain poorly known although its prognostic value has been established.
  
  
  OBJECTIVE
  To investigate the effects of a stable, long-acting, selective A1-adenosine receptor agonist, SDZ WAG994, on heart rate during exercise and on HRV.
  
  
  METHODS
  In a multicenter, double-blind, randomized, placebo-controlled, parallel group study, patients with permanent AF performed a symptom-limited exercise test and underwent 24-hour ECG monitoring on day 1 during treatment with placebo, and on day 2 during treatment with either placebo or 2 mg SDZWAG994 orally. Changes in mean heart rate during exercise and changes in HRV indices between day 1 and day 2 were compared between the two groups.
  
  
  RESULTS
  Thirty-two patients (64 +/- 8 years; 81% male; 25% in NYHA Class II; 38% with no structural heart disease) were included in the study. During active treatments, heart rate remained unchanged at rest and increased significantly during exercise. A significant daytime increase in short-term HRV indices (DpNN50 = 4.5% P = 0.01; DrMSSD = 6% P = 0.03; DSDNN Index = 6% P = 0.02) occurred during active treatment.
  
  
  CONCLUSIONS
  Selective A1-adenosine receptor agonism with SDZ/WAG994 limits the increase in mean heart rate during exercise in patients with AF. In addition, this agonist selectively increases short-term HRV indices, suggesting that pNN50, rMSSD, and SDNN reflect vagal influences during AF.
authors.affiliation: Service de Cardiologie, Hôpital Broussais, Paris, France.
authors.forename: O
authors.initials: O
authors.lastname: Piot
authors.forename: C
authors.initials: C
authors.lastname: Chauvel
authors.forename: A
authors.initials: A
authors.lastname: Lazarus
authors.forename: D
authors.initials: D
authors.lastname: Pellerin
authors.forename: D
authors.initials: D
authors.lastname: David
authors.forename: L
authors.initials: L
authors.lastname: Leneveut-Ledoux
authors.forename: L
authors.initials: L
authors.lastname: Guize
authors.forename: J Y
authors.initials: JY
authors.lastname: Le Heuzey
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D004311:Double-Blind Method; D015716:Electrocardiography, Ambulatory; D005080:Exercise Test; D005260:Female; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012815:Signal Processing, Computer-Assisted
chemical_list: D000889:Anti-Arrhythmia Agents; C090949:N(6)-cyclohexyl-2-O-methyladenosine; D000241:Adenosine